Association between dd‐cfDNA levels, de novo donor specific antibodies, and eGFR decline: An analysis of the DART cohort

Abstract

Abnormalities in dd-cfDNA levels are associated with clinical parameters commonly used as surrogate endpoints for adverse allograft outcomes, raising the possibility that molecular injury as characterized by dd-cfDNA could help identify patients at risk of these outcomes.